Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sitagliptin + metformin + placebo
- Development stage
- Phase 4
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Sitagliptin + metformin + placebo is a combination regimen used as an active comparator arm in clinical trials, specifically the TRIAD Phase 3 trial sponsored by Eurofarma. It consists of sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin levels to stimulate insulin secretion, and metformin, a biguanide that reduces hepatic glucose production and improves insulin sensitivity. The placebo component is used to maintain the double-blind nature of the study, typically substituting for a third active agent like dapagliflozin. This combination is evaluated for the treatment of type 2 diabetes mellitus in patients with inadequate glycemic control on metformin monotherapy.
- Brand names
- Alosita-Met
- Other names
- sitagliptin + metformin
02
Targets
DPP-4 (Dipeptidyl Peptidase-IV)ND1 (Mitochondrial electron transport chain complex I)GPD2 (Glycerol-3-phosphate dehydrogenase 2)AMPK (Adenosine monophosphate–activated protein kinase)
Beyond the preview
Go deeper on sitagliptin + metformin + placebo.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sitagliptin + metformin + placebo.